Analyst Ratings for Silver Standard Resources Inc. (SSRI)

Updated: 2017-07-27

Silver Standard Resources Inc. (NASDAQ:SSRI) was awarded an average rating of Overweight from investment analysts following the stock. About 30 days ago, SSRI was issued an average rating of Overweight.

Of the 10 analysts covering the stock, 5 gave it a buy rating, 1 issued an overweight rating, 4 issued a hold rating, 0 issued an underweight rating, and 0 issued a sell rating. Over the past 90 days, the number of analysts that are bullish on the stock has increased by 1. During this time, the number of analysts bearish on the stock has increased by 0.

A number of analysts gave price targets for SSRI. The most optimistic price target was 17.26, implying a possible profit of 80.53 percent. The lowest price target was 10.56, implying a possible loss of 10.45 percent. One must be careful with overanalyzing price targets and ratings due to possible conflicts of interest among the analysts releasing them.

Analysts have revised their earnings estimates downwards for this quarter, by about -0.89 percent on average, compared to last month. The average change in earnings estimates over the last 90 days is 0 percent. Over the past 30 days, FY earnings estimates have also changed downwards by -12.57 percent. Expanding the time horizon to 3 months, the average change in fiscal year estimates becomes 0 percent.

Another thing investors often look at is the level of agreement among analysts' revisions. 0 analysts have revised their quarterly estimates upwards in the past 30 days, which can be compared to the 2 analysts that decreased their estimates. During this time, 0 analysts made positive revisions in their estimates for this fiscal year's earnings, compared to 2 analysts that revised their FY estimates downwards.

The growth rate of SSRI's earnings is estimated by analysts to be -53.99 percent. People on Wall Street often look at a company's PEG ratio. A lower PEG ratio is favorable, because people typically see that as an indicator of higher growth relative to stock price. PEG ratios below 1 are often considered desirable, but many choose to perform ratio comparisons with other companies in the industry. SSRI has a PEG ratio of -0.27.

In the last 52-weeks, SSRI has achieved a high of 15.84 and a low of 7.70. Currently the stock is 24.17 percent higher than its low, and 39.64 percent below the high. SSRI has a P/E ratio of 14.59. Investors typically compare the P/E ratio to a company's peers in the industry. The SSRI value stock report compares SSRI to some of its peers using value stock charts. The market cap of SSRI is $1.17 billion. SSRI is estimated to release their earnings results for the quarter on 0000-00-00, days from today.